Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PDE4B | Q07343 | 2/20 | 0.54 |
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.53 |
| ▸ | HPGD | P15428 | 3/20 | 0.53 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.53 |
| ▸ | HTT | P42858 | 1/20 | 0.50 |
| ▸ | TP53 | P04637 | 1/20 | 0.50 |
| ▸ | UBE2M | P61081 | 1/20 | 0.49 |
| ▸ | DCUN1D1 | Q96GG9 | 1/20 | 0.49 |
| ▸ | AKR1C3 | P42330 | 1/20 | 0.48 |
| ▸ | ABHD6 | Q9BV23 | 1/20 | 0.48 |
| ▸ | NPC1 | O15118 | 1/20 | 0.47 |
| ▸ | CASP3 | P42574 | 1/20 | 0.47 |
| ▸ | RAB9A | P51151 | 1/20 | 0.47 |
| ▸ | SENP8 | Q96LD8 | 1/20 | 0.47 |
| ▸ | SENP7 | Q9BQF6 | 1/20 | 0.47 |
| ▸ | SENP6 | Q9GZR1 | 1/20 | 0.47 |
| ▸ | PKM | P14618 | 1/20 | 0.47 |
| ▸ | MEN1 | O00255 | 1/20 | 0.47 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.47 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL8233979 | 0.85 | HPGD (0.71) | PDE4BALDH1A1HPGDSMN1; SMN2HTT | |
| SCHEMBL8242223 | 0.85 | PDE4B (0.57) | PDE4BALDH1A1HPGDSMN1; SMN2HTT | |
| SCHEMBL8243015 | 0.82 | PDE4B (0.56) | PDE4BALDH1A1HPGDSMN1; SMN2NPC1 | |
| SCHEMBL13912857 | 0.82 | CA1 (0.62) | PDE4BAKR1C3ABHD6KMT2ACA1 | |
| SCHEMBL20439780 | 0.80 | HPGD (0.59) | PDE4BALDH1A1HPGDSMN1; SMN2HTT | |
| SCHEMBL8240427 | 0.80 | PDE4B (0.57) | PDE4BALDH1A1HPGDSMN1; SMN2HTT | |
| SCHEMBL20046991 | 0.80 | MAPK1 (0.51) | ALDH1A1HPGDSMN1; SMN2HTTTP53 | |
| SCHEMBL30267796 | 0.79 | PDE4B (0.80) | PDE4BALDH1A1NPC1RAB9APKM | |
| SCHEMBL30267843 | 0.79 | PDE4B (0.80) | PDE4BALDH1A1NPC1RAB9APKM | |
| SCHEMBL7894613 | 0.79 | PDE4B (0.80) | PDE4BALDH1A1NPC1RAB9APKM |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11746097-B2 | LXR inverse agonists for treatment of cancer | SAINT LOUIS UNIVERSITY (US) | 2023-09-05 | — | — | US | disclosed |
| US-11746097-B2 | LXR inverse agonists for treatment of cancer | SAINT LOUIS UNIVERSITY (US) | 2023-09-05 | — | — | US | disclosed |
| US-20200308135-A1 | LXR INVERSE AGONISTS FOR TREATMENT OF CANCER | SAINT LOUIS UNIVERSITY (US) | 2020-10-01 | — | — | US | disclosed |
| WO-2017223514-A9 | LXR INVERSE AGONISTS FOR TREATMENT OF CANCER | SAINT LOUIS UNIVERSITY (US) | 2018-04-12 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20200308135-A1 | LXR INVERSE AGONISTS FOR TREATMENT OF CANCER | NR1H2, NR1H3, PPARD | PDE4B 894/4885ALDH1A1 2432/4885HPGD 941/4885 |
| US-11746097-B2 | LXR inverse agonists for treatment of cancer | NR1H2, NR1H3, PPARD | PDE4B 894/4885ALDH1A1 2432/4885HPGD 941/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.